Ductus Arteriosus, Patent Clinical Trial
Official title:
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03604796 -
Alternative Paracetamol Treatments for the Neonate With a hsPDA
|
Phase 2/Phase 3 | |
Completed |
NCT00000494 -
Management of Patent Ductus in Premature Infants
|
Phase 3 | |
Completed |
NCT01251939 -
Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious
|
N/A | |
Completed |
NCT01031316 -
Patent Ductus Arteriosus (PDA) Screening Trial
|
N/A | |
Completed |
NCT00828334 -
NIT-OCCLUD PDA Phase II Sentinel Trial
|
N/A | |
Completed |
NCT00009646 -
Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
|
Phase 3 | |
Withdrawn |
NCT00470743 -
Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies
|
Phase 4 | |
Completed |
NCT00725647 -
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
|
N/A | |
Terminated |
NCT00239512 -
New Management Strategy of PDA for VLBW Preterm Infants
|
N/A | |
Recruiting |
NCT04508036 -
Ductus Arteriosus Closure and D-Dimer and Fibrinogen Levels
|
||
Completed |
NCT01243996 -
High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant
|
Phase 2/Phase 3 | |
Completed |
NCT00005190 -
Reproduction and Survival After Cardiac Defect Repair
|
N/A | |
Not yet recruiting |
NCT04205877 -
The U.S. PDA Registry
|
||
Completed |
NCT02422966 -
Paracetamol in Patent Ductus Arteriosus
|
Phase 2 | |
Completed |
NCT02803671 -
Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data
|
N/A | |
Completed |
NCT00799123 -
Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants
|
N/A | |
Completed |
NCT00528736 -
Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks
|
N/A | |
Completed |
NCT02002741 -
Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants
|
Phase 2/Phase 3 |